Gastroenterology ·
Elebsiran-tobevibart meets phase 3 hepatitis delta goal; efinopegdutide resolves MASH in phase 2b; dabigatran recanalizes portal vein thrombosis

Listen to this post
read by AI voices · all episodesTHE SHORT READ
Vir Biotechnology said 44% of patients given elebsiran and tobevibart reached undetectable hepatitis delta virus RNA with ALT normalization at week 48 in the phase 3 ECLIPSE 1 trial.
Efinopegdutide resolved MASH in up to 63% of patients versus 13% with placebo in a phase 2b trial, and dabigatran recanalized portal vein thrombosis in 64.3% versus 21.4% with placebo in cirrhosis.
THE DETAILS
- Research Nov 8, 2026Vir Biotechnology said 44% of patients given monthly subcutaneous elebsiran and tobevibart achieved undetectable hepatitis delta virus RNA with alanine aminotransferase normalization at week 48, the primary end point, versus 0% in the delayed-treatment group at week 12 (P < .0001), in the 124-patient phase 3 trial randomized 2:1. Undetectable virus at week 48, a key secondary end point, was reached by 79%. The topline results were presented in a late-breaking oral session at The Liver Meeting 2026, HCPLive reported Nov. 8, and Vir said it plans a U.S. filing in mid-2027.
- Research Nov 9, 2026In a randomized, placebo-controlled phase 2b trial of 381 adults with biopsy-proven MASH and F2 or F3 fibrosis, presented at The Liver Meeting with simultaneous publication in The Lancet, MASH resolution without worsening of fibrosis, the primary end point, occurred at week 52 in 56%, 63% and 61% with once-weekly efinopegdutide 4, 7 and 10 mg versus 13% with placebo, HCPLive reported. Fibrosis improved by at least one stage in 52% at 7 mg versus 21% with placebo. Merck is developing the drug, and investigators concluded the 7 mg dose had the most favorable benefit-risk profile.
- Research Nov 12, 2026In the double-blind DAB-PVT trial, published Nov. 12 in The American Journal of Gastroenterology, 84 patients with cirrhosis and chronic portal vein thrombosis were randomized to dabigatran 150 mg twice daily or placebo for 12 months. Complete recanalization of the portal vein at 12 months, the primary end point, occurred in 27 of 42 (64.3%) patients with dabigatran versus 9 of 42 (21.4%) with placebo (P < .001). Variceal bleeding episodes numbered 3 versus 12 (P = .008).
- Research Nov 11, 2026Among 718 identified PRSS1 carriers in a nationwide French hereditary pancreatitis cohort published Nov. 11 in Clinical Gastroenterology and Hepatology, 455 had follow-up. Median age at symptom onset was 12.5 years and penetrance was 77.6%. Cumulative pancreatic ductal adenocarcinoma risk was 2.0% by age 50 and 5.9% by age 60, with a standardized incidence ratio of 32.2 (95% CI 19.4 to 50.3), and diabetes was independently associated with higher pancreatic cancer risk.
The weekly innovation roundup for gastroenterology, published every Sunday for the week before; every item links to its sources. Latest gastroenterology news · All specialties